Analysis: Regulatory pathway for biosimilars is still unclear

11/2/2010 | Reuters

Although FDA officials have started discussing the creation of a regulatory pathway for approving biosimilars, the agency has not set a deadline for the implementation of such a system, and it could take at least five years for such drugs to reach the market, experts said. "People will be frustrated. It's not going to be a clear pathway for everything," said Ian Spatz, a policy consultant in Washington, D.C., and a former executive at Merck & Co.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL